Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

Executive Summary

Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.

You may also be interested in...



Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes

Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.

Lilly/Loxo Deal Came Together Quickly

Lilly's $8bn acquisition of genetics-based cancer specialist Loxo Oncology didn't involve any other bidders and was finalized in just days over the holidays as Lilly sought to make a news splash at the J.P. Morgan Healthcare conference, according to an SEC filing.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC003326

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel